Spending More or Less, and on What? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
Spending More or Less, and on What?
Pharmaceutical Technology's annual survey on equipment and machinery reveals the spending levels and types of spending made in 2009 and planned for 2010.
Apr 2, 2010
By: Patricia Van Arnum
Pharmaceutical Technology
Volume 34, Issue 4, pp. 48-56
« Previous
123

Innovation


Figure 5
Innovation is an important consideration in purchasing decisions. The survey showed that 16.1% of respondents said that innovation is "extremely important" in their purchasing decisions, and 47.7% said it was "very important." Respondents were fairly favorable in evaluating the level of innovation in equipment and machinery during the past two years (2008 and 2009) (see Figure 5). Almost one-quarter of respondents said that innovation in machinery and equipment for quality assurance and control was "high," and 50.7% ranked the level of innovation as "medium" (see Figure 5).


Figure 6:
Respondents felt innovation was highest in disposables or single-use components for biopharmceutical manufacturing, followed by process control and automation, and analytical instrumentation (See Figure 6). Product areas that showed the lowest levels of innovation according to survey respondents were vial- or syringe-filling and tablet presses or capsule-filling machines. Almost half of the respondents (49%) said there has been "none or low" innovation in equipment for vial- or syringe-filling, and 47.6% said there has been "none or low" innovation for tablet presses or capsule-filling machines during the past two years (see Figure 6).


Respondents profile

QbD and PAT


Figure 7:
Among survey respondents, adoption of PAT was low. Two-thirds of respondents (67.1%) said that their company does not incorporate PAT into its manufacturing processes, and 32.9% of companies said they have incorporated PAT. For those companies that do incorporate PAT, the leading benefit cited by respondents was better process understanding (73% of respondents cited as a benefit) (see Figure 7). Almost half of the respondents using PAT said that it increased efficiency and reduced waste.


Figure 8:
Cost–benefit factors were the leading reasons for companies not incorporating PAT into their manufacturing processes. Almost one-third of respondents (31.8%) said that "benefits do not justify the effort to implement" (see Figure 8). One-quarter of respondents said PAT implementation was too costly, and one-quarter also said that their companies do not use PAT because it would require new equipment or procedures (see Figure 8).

« Previous
123

ADVERTISEMENT

blog comments powered by Disqus
About the Author

Patricia Van Arnum

Executive Editor, Pharmaceutical Technology

Articles by Patricia Van Arnum
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Featured Jobs

More Jobs
Source: Pharmaceutical Technology, 4/2/2010
 Click here